These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 8915698)
21. Effect of hepatobiliary disease, chronic hepatitis C and hepatitis B virus infections and interferon-alpha on porphyrin profiles in plasma, urine and faeces. Gibson PR; Grant J; Cronin V; Blake D; Ratnaike S J Gastroenterol Hepatol; 2000 Feb; 15(2):192-201. PubMed ID: 10735544 [TBL] [Abstract][Full Text] [Related]
22. The difference in liver pathology between sporadic and familial forms of porphyria cutanea tarda: the role of iron. Siersema PD; Rademakers LH; Cleton MI; ten Kate FJ; de Bruijn WC; Marx JJ; Wilson JH J Hepatol; 1995 Sep; 23(3):259-67. PubMed ID: 8550989 [TBL] [Abstract][Full Text] [Related]
23. [Anesthesia with propofol and atracurium in a case of porphyria cutanea tarda]. Baratto F; Meggiolaro M Minerva Anestesiol; 1998 Nov; 64(11):535-9. PubMed ID: 9951273 [TBL] [Abstract][Full Text] [Related]
24. Cimetidine Does Not Inhibit 5-Aminolevulinic Acid Synthase or Heme Oxygenase Activity: Implications for Treatment of Acute Intermittent Porphyria and Erythropoietic Protoporphyria. Yasuda M; Lee S; Gan L; Bergonia HA; Desnick RJ; Phillips JD Biomolecules; 2023 Dec; 14(1):. PubMed ID: 38254627 [TBL] [Abstract][Full Text] [Related]
25. [Sclerodermatous changes in porphyria cutanea tarda: six cases]. Khayat R; Dupuy A; Pansé I; Bagot M; Cordoliani F Ann Dermatol Venereol; 2013 Oct; 140(10):589-97. PubMed ID: 24090888 [TBL] [Abstract][Full Text] [Related]
28. Porphyria cutanea tarda symptomatica (PCT-S). A study of the effect of phlebotomy therapy. Epstein JH; Redeker AG Arch Dermatol; 1965 Sep; 92(3):286-9; discussion 289-90. PubMed ID: 11851252 [TBL] [Abstract][Full Text] [Related]
29. Urinary porphyrin excretion in various types of porphyria. Thin-layer chromatographic study. Perrot H; Boucherat M; Gardella C Dermatologica; 1980; 161(3):167-78. PubMed ID: 7398995 [TBL] [Abstract][Full Text] [Related]
30. Disappearance of multiple hyperechoic liver nodules in sporadic porphyria cutanea tarda after treatment with ledipasvir/sofosbuvir for hepatitis C. Takata K; Shakado S; Sakamoto K; Fukuda H; Yamauchi R; Fukuda S; Kunimoto H; Umeda K; Tanaka T; Yokoyama K; Morihara D; Takeyama Y; Irie M; Sakisaka S Clin J Gastroenterol; 2017 Oct; 10(5):459-463. PubMed ID: 28884440 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of porphyria cutanea tarda in U.S. workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Calvert GM; Sweeney MH; Fingerhut MA; Hornung RW; Halperin WE Am J Ind Med; 1994 Apr; 25(4):559-71. PubMed ID: 7912041 [TBL] [Abstract][Full Text] [Related]
32. High-dose vitamin E lowers urine porphyrin levels in patients affected by porphyria cutanea tarda. Pinelli A; Trivulzio S; Tomasoni L; Bertolini B; Pinelli G Pharmacol Res; 2002 Apr; 45(4):355-9. PubMed ID: 12030801 [TBL] [Abstract][Full Text] [Related]
33. The role of iron in experimental porphyria and porphyria cutanea tarda. Siersema PD; van Helvoirt RP; Cleton-Soeteman MI; de Bruijn WC; Wilson JH; van Eijk HG Biol Trace Elem Res; 1992 Oct; 35(1):65-72. PubMed ID: 1384628 [TBL] [Abstract][Full Text] [Related]
34. Cytochrome P450 induction, uroporphyrinogen decarboxylase depression, porphyrin accumulation and excretion, and gender influence in a 3-week rat model of porphyria cutanea tarda. Franklin MR; Phillips JD; Kushner JP Toxicol Appl Pharmacol; 1997 Dec; 147(2):289-99. PubMed ID: 9439724 [TBL] [Abstract][Full Text] [Related]
35. Isolation and characterization of new porphyrin metabolites in human porphyria cutanea tarda and in rats treated with hexachlorobenzene by HPTLC, HPLC and liquid secondary ion mass spectrometry. Luo J; Lim CK Biomed Chromatogr; 1995; 9(3):113-22. PubMed ID: 7655298 [TBL] [Abstract][Full Text] [Related]
36. Effects of vitamin E administration on the hemorheological status and redox homeostasis of patients with porphyria cutanea tarda treated with phlebotomy. Székely E; Vereckei A; Almási A; Rapavi E; Tasnádi G; Várnai K; Pallai Z; Lugasi A; Blázovics A Clin Hemorheol Microcirc; 2007; 36(1):13-23. PubMed ID: 17211058 [TBL] [Abstract][Full Text] [Related]
37. Association between porphyria cutanea tarda and beta-thalassemia major. Barbieri L; Macrì A; Lupia Palmieri G; Aurizi C; Biolcati G Cell Mol Biol (Noisy-le-grand); 2009 Jul; 55(2):36-9. PubMed ID: 19656449 [TBL] [Abstract][Full Text] [Related]
38. Deferasirox for porphyria cutanea tarda: a pilot study. Pandya AG; Nezafati KA; Ashe-Randolph M; Yalamanchili R Arch Dermatol; 2012 Aug; 148(8):898-901. PubMed ID: 22911183 [TBL] [Abstract][Full Text] [Related]
39. [Porphyria cutanea tarda presenting as jaundice]. Park KH; Park DY; Kim JB; Baek IH; Lee MS; Baik GH; Park SH; Kim JH; Park CK; Kim KH Korean J Hepatol; 2004 Dec; 10(4):308-12. PubMed ID: 15613806 [TBL] [Abstract][Full Text] [Related]
40. Desferrioxamine treatment of porphyria cutanea tarda in a patient with HIV and chronic renal failure. Vasconcelos P; Luz-Rodrigues H; Santos C; Filipe P Dermatol Ther; 2014; 27(1):16-8. PubMed ID: 24502304 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]